Fluidigm Europe has
announced a new technical report that describes experimentation on a normal
human genomic DNA sample using a prototype 200k Digital Array Chip on a
modified BioMark
TM System.
Fluidigm's commercial Digital Array chips provide a flexible and robust
platform to perform digital PCR and have been used in sample quantitation, rare
mutation detection, haplotyping, and copy number variation studies. The new
200k chip prototype is more powerful and enables an even more precise and
accurate measurement of target copy number.
Two forms of commercial Digital Array chips are currently available, which have
configurations known as 12.765 and 48.770 (with 9,180 and 36,960 reaction
chambers each). In this new report the authors show a prototype 200,000 chamber
version of the Fluidigm Digital Array chip and demonstrate that the
experimental process is further simplified and the copy numbers of two single
copy genes (RnaseP and RPP30) can be measured at a much greater accuracy.
The BioMark HD system is the latest and most advanced real-time PCR system
developed by Fluidigm. The system provides you with the ability to use a
wide variety of sample types, multiple chemistry choices, and an industry
leading degree of flexibility. The system offers unparalleled throughput for
real-time PCR and digital PCR, integrating thermal cycling and fluorescence
detection on Integrated Fluidic Circuits (IFCs). The BioMark system used for
the 200k chip experiments was modified by the addition of a higher resolution
CCD camera.
A copy of the technical poster may be downloaded from
www.fluidigm.com/home/fluidigm/Posters/Poster_AMN_2011_200K_dPCR.pdf
or is available on request by contacting
info-europe@fluidigm.com.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems
for growth markets in the life science and agricultural biotechnology, or
Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of
instruments and consumables, including chips and reagents. These systems are
designed to significantly simplify experimental workflow, increase throughput
and reduce costs, while providing the excellent data quality demanded by
customers. Fluidigm actively markets three microfluidic systems including eight
different commercial chips to leading pharmaceutical and biotechnology
companies, academic institutions and Ag-Bio companies. For more
information, please visit
www.fluidigm.com.
* Fluidigm, the Fluidigm logo, BioMark, Access Array, Dynamic Array, Digital
Array, FC1, Topaz, and NanoFlex are trademarks or registered trademarks of
Fluidigm Corporation
